GOVX · GeoVax Labs, Inc. · Executive Compensation
$0.19
-0.01 (-5.63%)
At close · Oct 26
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jul 27, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors collectively raise substantial doubt about the Company’s ability to continue as a going concern. Management believes that we will be successful in securing the additional capital required to continue the Company’s planned operations, but that our plans do not fully alleviate the substantial doubt about the Company’s ability to operate as a going concern.”View the 10-Q filed Jul 27, 2026
Market Cap
$1.52M
Shares
7.37M
Volume · Oct 26
226.45K
Avg daily vol (3M)
762.64K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Kelly McKee | Chief Medical Officer | $361,034 |
| Mark Newman | Chief Scientific Officer | $291,500 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| David A. Dodd | President and CEO | $652,012 |
| Mark Newman | Chief Scientific Officer | $437,366 |
| Mark Reynolds | Chief Financial Officer | $421,400 |
| Kelly McKee | Chief Medical Officer | $362,580 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| David A. Dodd | President and CEO | $677,110 |
| Mark Reynolds | Chief Financial Officer | $478,326 |
| Mark Newman | Chief Scientific Officer | $248,759 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| David A. Dodd | President and CEO | $726,743 |
| Mark Reynolds | Chief Financial Officer | $500,751 |
| Farshad Guirakhoo | Former Chief Scientific Officer | $163,321 |
| Mark Newman | Chief Scientific Officer | $99,617 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Farshad Guirakhoo | Former Chief Scientific Officer | $271,648 |
| David A. Dodd | President and CEO | $250,914 |
| Mark Reynolds | Chief Financial Officer | $240,017 |
| Mark Newman | Chief Scientific Officer | — |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Farshad Guirakhoo | Chief Scientific Officer | $282,675 |
| Mark Reynolds | Chief Financial Officer | $253,406 |
| David A. Dodd | President and CEO | $157,283 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| John N. Spencer, Jr. | Director | Appointed | 2023-08-02 |
| Jayne Morgan | Director | Appointed | 2023-08-02 |
| Nicole Lemerond | Director | Appointed | 2023-08-02 |
| Robert T. McNally | Director | Appointed | 2023-08-02 |
| Dean G. Kollintzas | Director | Appointed | 2023-08-02 |
| David A. Dodd | Director | Appointed | 2023-08-02 |
| Randal D. Chase | Director | Appointed | 2023-08-02 |
| Jayne Morgan, M.D. | to the Board | Appointed | 2022-12-08 |
| Nicole Lemerond | Board of Directors | Appointed | 2022-09-01 |
Leadership
- David A. Dodd CEO, Board Member
- Mark Reynolds CFO
- Dean G. Kollintzas Board Member
- Jayne Morgan Board Member
- Jayne Morgan, M.D. Board Member
- John N. Spencer Board Member
- John N. Spencer, Jr. Board Member
- Nicole Lemerond Board Member
- Randal D. Chase Board Member
- Robert T. McNally Board Member